Document is current
Any future updates will be listed below
-
Authors
Shields, Alan L.
Taylor, Fiona https://orcid.org/0000-0001-6474-4314
Lamoureux, Roger E.
Padilla, Brad
Severson, Kas
Green, Tanya
Boral, Anthony L.
Akin, Cem
Siebenhaar, Frank
Mar, Brenton
-
Funding
Funding for this research was provided by:
Blueprint Medicines
- License Information
-
More Information
Article History
Received: 6 October 2021
Accepted: 11 March 2023
First Online: 25 March 2023
Declarations
:
: Participants were recruited through an advocacy group with study materials approved by a centralized IRB, Schulman IRB.
: Not applicable.
: ALS, FT, REL, BP, and KS are employees of Adelphi Values, which conducted research on behalf of Blueprint Medicines. TG, ALB, and BM are employees of Blueprint Medicines and own stock in the company. CA received research funding and consultancy fees from Blueprint Medicines. FS is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Blueprint, Celldex, Genentech, Moxie, Novartis, and Uriach.
